An innovative mushroom extract-based pharmaceutical product to help opioid use disorder patients withdraw from opioid use

PsiClone是一家总部位于英国的药物开发中小企业，其核心项目团队由Adam乔治（GW Pharmaceuticals的首席执行官/前首席财务官兼研发联席负责人）和Dean Putt（首席运营官/受控药物专家）组成。阿片类药物成瘾已达到流行病水平，是一个重大的全球问题。来自美国的数据表明，2017年阿片类药物成瘾的经济成本约为1万亿美元。美国有120万“维持性成瘾者”-那些处方阿片类药物维持疗法，这无助于帮助患者退出阿片类药物的使用。目前的阿片类药物替代疗法使患者处于受控成瘾状态，无法恢复正常的家庭生活，需要每天监督美沙酮或丁丙诺啡给药，这些阿片类药物具有转移和滥用的高风险。在那些设法退出阿片类药物使用的人中，70%在一年内复发。在美国，阿片类药物滥用的年死亡率为10万。英国有25万名处方美沙酮使用者，面临类似的问题，但没有那么严重。迫切需要替代非阿片类药物治疗方案。临床试验表明，裸盖菇中天然存在的分子有望成为治疗严重抑郁症和成瘾的潜在药物。PsiClone正在开发一种基于蘑菇提取物的药品，以帮助阿片类药物使用障碍（OUD）患者退出阿片类药物的使用。任何可以帮助患者实现清醒的药品都将产生巨大的社会影响。与毒品有关的犯罪的社会代价、对家庭生活的影响以及与药物滥用、死亡和毒品犯罪有关的反社会行为，都可以通过一种新的有效治疗办法来减少。

PsiClone is a UK-based pharmaceutical development SME with a core project team of Adam George (CEO/former CFO and joint head of R&D at GW Pharmaceuticals) and Dean Putt (COO/Controlled drug specialist).Opioid addiction has reached epidemic levels and is a major global issue. Figures from the US indicate that the economic cost of opioid addiction was ~$1T in 2017\. There are 1.2M US 'maintained addicts'-- those prescribed opioid maintenance therapies, which do nothing to help patients withdraw from opioid use. There are no alternatives available and little development is taking place.Current opioid substitution therapies maintain patients in a state of controlled addiction, unable to return to normal family life, requiring daily supervised methadone or buprenophine dosing with these opioid products at high risk of diversion and abuse. Of those who do manage to withdraw from opioid use, 70% relapse within a year. The annual death rate in the US from opioid misuse is 100K.With 250,000 prescribed Methadone users, the UK suffers similar, though not as severe, issues.Alternative non-opioid pharmaceutical treatment options are urgently needed. Clinical trials indicate that molecules found naturally in Psilocybe mushrooms show promise as potential treatments for severe depression and addiction. PsiClone is developing a mushroom extract-based pharmaceutical product to help opioid use disorder (OUD) patients withdraw from opioid use.Any pharmaceutical product that can help patients achieve sobriety would have a dramatic societal impact. The societal costs of drug-related crime, the impact on family life and antisocial behaviour associated with drug abuse, deaths and drug crime could all be reduced by a new effective treatment option.